Introduction: The precise etiology of alopecia areata (AA) remains unclear. Various treatments, including corticosteroids, minoxidil, immunotherapy, and phototherapy, have shown varying efficacy. Injectable corticosteroids, despite being invasive, are the first-line treatment, while topical steroids are also commonly used.
Objective: To compare the efficacy of intralesional steroid (triamcinolone acetate) versus cryotherapy for the treatment of alopecia areata over a 6-month period in the Department of Dermatology at the Pakistan Atomic Energy Commission General Hospital.
Methods: The study included 118 patients (aged 15 to 50 years, both genders) with a single patch of alopecia areata on the scalp. Exclusion criteria included active secondary infections, cold intolerance, multiple patches, iatrogenic or primary immunosuppression, pregnancy, or breastfeeding. Patients were randomly assigned to two groups: Group A received intralesional steroid injections, and Group B underwent cryotherapy with liquid nitrogen. Treatment efficacy was then evaluated.
Results: The mean age was 27.78 +/- 4.68 years in Group A and 26.63 +/- 4.91 years in Group B. Most patients (95, 80.51%) were aged 15 to 30 years. Males predominated with 86 (72.27%) participants, resulting in a male-to-female ratio of 2.6:1. The mean duration of alopecia areata was similar in Group A (8.51 +/- 3.94 months) and Group B (8.39 +/- 3.13 months). Group A (intralesional corticosteroids) had a significantly higher efficacy rate, with 49 patients (83.05%) responding positively, compared to 30 patients (50.85%) in Group B (cryotherapy) (P=0.0001), as shown in Table 1.
Conclusion: The study concluded that the efficacy of intralesional steroids may be superior to cryotherapy for the treatment of alopecia areata. J Drugs Dermatol. 2025;24(3):294-297. doi:10.36849/JDD.8499.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.36849/JDD.8499 | DOI Listing |
Diagnostics (Basel)
February 2025
Discipline of Dermatology, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.
Atopic dermatitis (AD) and alopecia areata (AA) frequently coexist due to shared immune-mediated mechanisms. Treatments targeting AD, including Janus kinase (JAK) inhibitors and dupilumab, may impact AA outcomes in unpredictable ways. This study aims to evaluate the effects of advanced therapies on patients with concurrent AD and AA to inform treatment strategies.
View Article and Find Full Text PDFInt J Dermatol
March 2025
Dermatology Unit, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Arch Dermatol Res
March 2025
Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA.
J Cutan Med Surg
March 2025
Assistant Professor, Temerty Faculty of Medicine, University of Toronto; DermAtelier On Avenue - Medical and Cosmetic Dermatology, Toronto, ON, Canada.
Background: The Ontario Health Insurance Plan (OHIP) insures appointments for the assessment and diagnosis of hair loss, or alopecia. Although anecdotal, discussion suggests that, increasingly, dermatologists decline to see referrals of this nature. There has been a lack of objective surveillance to determine the proportion of dermatologists in practice who accept referrals for this concern.
View Article and Find Full Text PDFDermatol Surg
March 2025
All authors are affiliated with the Dermatology Department, Cairo University, Cairo, Egypt.
Background: Alopecia areata (AA) is a common autoimmune disorder with significant psychosocial burden. Intralesional corticosteroid (ILCS) injection is considered the main line of management. More tolerable treatment methods with less side effects are needed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!